Application of magnolol or its combination with EGCG in inhibiting Mycoplasma gallisepticum and Mycoplasma synoviae.

Through the composition of Magnolia et al. and EGCG, the resistance of Mycoplasma chicken poison and Mycoplasma chicken synovialis to traditional antibiotics is solved, providing effective inhibition and killing effects, and providing new ways to prevent and treat Mycoplasma in poultry Drug selection reduces antibiotic dependence.

CN116509826BActive Publication Date: 2024-12-03INST OF ANIMAL SCI & VETERINARY HUBEI ACADEMY OF AGRI SCI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310105350.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-02-13
Publication Date
2024-12-03
Estimated Expiration
2043-02-13

AI Technical Summary

Technical Problem

Mycoplasma chicken poison and Mycoplasma chicken synovialis are highly resistant to traditional antibiotics, making it difficult for existing drugs to effectively control their infections and lack safe and efficient antibiotic replacements.

Method used

Using a composition of magnolol and EGCG, through different proportions (such as 1:32 or 1:16-32), it is used to prepare drugs to treat or prevent Mycoplasma chicken poison and Mycoplasma chicken synovialis infection, which significantly inhibits Or kill these microorganisms.

Benefits of technology

Magnolia and EGCG compositions show the effect of synergistically inhibiting and killing Mycoplasma chicken poison and Mycoplasma sacsus, providing new drug candidates for the prevention and treatment of Mycoplasma poultry and reducing antibiotic dependence.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
  • Figure SMS_4
    Figure SMS_4
Patent Text Reader

Abstract

The present invention belongs to the technical field of veterinary drugs, and specifically relates to the application of magnolol or a composition thereof with EGCG in inhibiting Mycoplasma gallisepticum and Mycoplasma synoviae. The magnolol composition provided by the present invention comprises: magnolol and EGCG, and the optimal ratio concentration for Mycoplasma gallisepticum and Mycoplasma synoviae is: magnolol: EGCG = 1.953 μg / mL: 62.5 μg / mL; the graded antibacterial concentration index is 0.375, magnolol and EGCG have a synergistic antibacterial effect on Mycoplasma gallisepticum and Mycoplasma synoviae, and the composition reduces the antibacterial concentration of magnolol and EGCG alone, saves costs, and has broad application prospects and development value in the fields of food processing, medicine, and aquaculture.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of veterinary drugs, and particularly relates to application of magnolol or a composition thereof with EGCG in inhibiting Mycoplasma gallisepticum and Mycoplasma synoviae. Background Art

[0002] Poultry mycoplasma disease is mainly caused by Mycoplasma gallisepticum and Mycoplasma synoviae, which can be transmitted horizontally and vertically. The main clinical symptoms are coughing, sneezing, respiratory rales, eye and nasal secretions, reduced feed intake and egg production, increased mortality, and decreased hatching rate. Mycoplasma mainly causes chronic and latent infections, increases the mixed infection and secondary infection of viruses and bacteria in poultry, and causes the morbidity and mortality of poultry to rise. Therefore, avian mycoplasma infection directly or indirectly causes huge losses in the poultry farming industry (Anneke Feberwee, Sjaak de Wit, Remco Dijkman, Clinical expression, epidemiology, and monitoring of Mycoplasma gallisepticum and Mycoplasma synoviae: an update. Avian Pathol. 2022 Feb; 51 (1): 2-18.).

[0003] Antibiotic treatment is one of the most effective strategies for controlling avian mycoplasma infection. However, due to the lack of cell wall, mycoplasma has natural resistance to antimicrobial drugs targeting peptidoglycan, such as β-lactams, glycopeptides and fosfomycin (Ken B Waites, Li Xiao, Yang Liu, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev. 2017 Jul; 30 (3): 747-809.). In addition, mycoplasma lacks the folate synthesis pathway and is resistant to sulfonamide antimicrobial drugs targeting the folate synthesis pathway (Fabricio BM Arraes, Maria José A. de Carvalho, Andrea Q. et al. Differential metabolism of Mycoplasma species as revealed by their genomes. Genetics and Molecular Biology, 30, 1, 182-189 (2007); KK Schultz, EL Strait, BZ Erickson, et al. Optimization of an antibiotic sensitivity assay for Mycoplasma hyosynoviae and susceptibility profiles of field isolates from 1997 to 2011. Vet Microbiol. 2012 Jul 6; 158 (1-2): 104-8.). In addition to the above drugs, polymyxin, nalidixic acid, rifampicin and some oxazolidinone drugs such as linezolid are also ineffective against mycoplasma (Ken B Waites, Li Xiao, Yang Liu, et al. Mycoplasma pneumoniae from the Respiratory Tract and Beyond. Clin Microbiol Rev. 2017 Jul; 30 (3): 747-809.). In summary, compared with bacteria, mycoplasmas lack some biosynthetic functions, and many drugs reported to be useful for bacteria or fungi are ineffective against mycoplasmas, resulting in relatively few drugs that can be used to treat mycoplasma infections.

[0004] There are large differences in the drug resistance of mycoplasmas from different sources. For example, the animal-derived Mycoplasma synoviae is seriously resistant to macrolides and fluoroquinolones (Zhang Huiru, Xiao Xia, Yang Tong, et al. Study on the drug resistance of Mycoplasma synoviae to commonly used antibiotics [J]. China Poultry. 2021, 43(04)); the human-derived genital mycoplasma is resistant to quinolones and aminoglycosides to varying degrees, but is highly sensitive to macrolides and tetracyclines (Wei Jingwen, Liu Enling, Liu Zhihui, et al. Analysis of 1006 cases of female genital mycoplasma infection and drug resistance [J]. Journal of North China University of Technology (Medical Edition). 2020, 22(02)). Therefore, it is an urgent need for the current poultry industry to find safe / efficient antibiotic alternatives to strengthen the prevention and control of poultry mycoplasma disease. Chinese herbal medicine not only has a regulating effect on the body, but also has an anti-infection effect on pathogenic microorganisms. It is an important source for the research and development of antibiotic alternatives.

[0005] Magnolol has antibacterial activity against Gram-negative and Gram-positive bacteria, but its specific antibacterial spectrum and antibacterial mechanism are not clear at present. It also has central muscle relaxation, anti-inflammatory, anti-tumor, anti-ulcer, antioxidant and other biological activities (Yiping Lin, Yuke Li, Yuanlian Zeng, et al. Pharmacology, Toxicity, Bioavailability, and Formulation of Magnolol: An Update. Front Pharmacol. 2021 Mar 17; 12: 632767.). The structural formula of Magnolol is as follows:

[0006]

[0007] EGCG is a catechin monomer isolated from tea leaves and is the main component of the biological activity of tea polyphenols. It is reported that EGCG has anti-cancer, antioxidant, anti-radiation, anti-aging, antibacterial, and antiviral effects. The structural formula of EGCG is as follows:

[0008]

[0009] In summary, mycoplasma is different from bacteria, and antibacterial drugs are not necessarily effective against mycoplasma. At present, there are no reports on the research of magnolol and magnolol and EGCG combination against mycoplasma. Summary of the invention

[0010] The technical problem to be solved by the present invention is to overcome the serious drug resistance of Mycoplasma galliscepticum and Mycoplasma synoviae, and provide application of magnolol in preparing drugs against Mycoplasma galliscepticum and Mycoplasma synoviae.

[0011] Another object of the present invention is to provide a use of a magnolol composition in a drug for treating and preventing Mycoplasma gallisepticum and Mycoplasma synoviae infection. The composition provided by the present invention has a good inhibitory and killing effect on Mycoplasma gallisepticum and Mycoplasma synoviae, and has a good application prospect in the prevention and treatment of avian mycoplasma disease.

[0012] To achieve the above purpose, this paper adopts the following technical solutions:

[0013] The invention discloses a method for preparing a drug for treating or preventing Mycoplasma gallisepticum and Mycoplasma synoviae infection, comprising using magnolol as an effective ingredient or one of the effective ingredients for preparing a drug for treating or preventing Mycoplasma gallisepticum and Mycoplasma synoviae infection, and for inhibiting or killing Mycoplasma gallisepticum and Mycoplasma synoviae in vitro.

[0014] The invention discloses an application of a magnolol composition in preparing a medicine for treating or preventing infection with Mycoplasma gallisepticum or Mycoplasma synoviae, comprising using the composition of the invention as the only effective ingredient for preparing a medicine for treating or preventing infection with Mycoplasma gallisepticum or Mycoplasma synoviae, and for inhibiting or killing Mycoplasma gallisepticum or Mycoplasma synoviae in vitro, wherein the only effective ingredients of the magnolol composition are magnolol and EGCG.

[0015] The above-mentioned composition, preferably, when used to prepare a drug for treating or preventing Mycoplasma gallisepticum infection, the mass ratio of magnolol to EGCG is 1:32;

[0016] The above-mentioned composition, preferably, when used to prepare a drug for treating or preventing chicken synoviae infection, the mass ratio of magnolol to EGCG is 1:16-32;

[0017] The above-mentioned composition, preferably, when used to inhibit Mycoplasma gallisepticum in vitro, the mass ratio of magnolol to EGCG is 1:32;

[0018] Preferably, when the above-mentioned composition is used to inhibit Mycoplasma synoviae in vitro, the mass ratio of magnolol to EGCG is 1:16-32.

[0019] Compared with the prior art, the present invention has the following advantages and effects:

[0020] The present invention provides for the first time that magnolol or magnolol and EGCG have a synergistic effect of inhibiting mycoplasma, and the composition can be used to resist Mycoplasma gallisepticum and Mycoplasma synoviae. The present invention studies and confirms through multiple methods that magnolol or a composition of magnolol and EGCG has a good inhibitory and killing effect on Mycoplasma gallisepticum and Mycoplasma synoviae, lays a theoretical foundation for the development of new drugs against poultry mycoplasma disease, and even provides candidate substances for the discovery of antibiotic substitutes, and has a good application prospect in the prevention and treatment of poultry mycoplasma disease. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 This is a dynamic analysis of the growth curve of magnolol against the growth of Mycoplasma gallisepticum.

[0022] Figure 2 This is a dynamic analysis of the growth curve of magnolol against the growth of chicken synoviae Mycoplasma.

[0023] Figure 3 This is a dynamic analysis of the growth curve of EGCG against the growth of Mycoplasma gallisepticum.

[0024] Figure 4 Dynamic analysis of the growth curve of EGCG against the growth of chicken synoviae Mycoplasma. DETAILED DESCRIPTION

[0025] The present invention is further described below in conjunction with the accompanying drawings and specific examples, but the examples do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the art.

[0026] Unless otherwise specified, the reagents and materials used in the following examples are commercially available. The present invention is described by taking Mycoplasma gallisepticum and Mycoplasma synoviae in avian mycoplasmas as examples. Mycoplasma gallisepticum and Mycoplasma synoviae used in the present invention are screened by the applicant. The applicant also screened multiple isolates of these two mycoplasmas. These isolates were tested using the same method as in the examples, and the results were the same as those disclosed in the examples.

[0027] The substance described in the present invention may also have an inhibitory and killing effect on other avian mycoplasmas. The structural formula of magnolol is as follows:

[0028]

[0029] Statistical analysis of the following examples of the present invention: All experiments were repeated at least 3 times independently, and the results were expressed as mean values ​​and standard errors, and analyzed using one-way analysis of variance and T test. All statistical analyses used P<0.05 as the test standard for significant statistical differences, and the analysis software was GraphPad Prism 8.

[0030] Embodiment 1:

[0031] Determination of minimum inhibitory concentration and minimum bactericidal concentration of magnolol against Mycoplasma gallisepticum and Mycoplasma synoviae:

[0032] 1. Materials

[0033] Modified Frey's medium is used for drug sensitivity experiments to detect the antibacterial efficacy of drugs.

[0034] 2. Test methods

[0035] The mycoplasma suspension cultured to the logarithmic growth phase was diluted to an appropriate concentration and added to sterile 96-well plates. 100 μL of the diluted mycoplasma suspension was added to wells 1 to 11 to make the final concentration of the mycoplasma suspension in each well 10 5 CCU / mL;

[0036] The magnolol solution was diluted in multiples with modified Frey's medium, and magnolol solutions of different concentrations were added to the above-mentioned 96-well plate. The diluted magnolol solution was added to wells 1 to 10, 100 μL per well, and 100 μL of modified Frey's medium was added to well 11 to form a 200 μL mycoplasma suspension as a growth control. Only 200 μL of modified Frey's medium was added to well 12 as a negative control.

[0037] Place the 96-well plate in a 37°C 5% CO2 incubator for 48 hours, observe the color change of the culture medium in the 96-well plate, and determine the MIC value. Take the bacterial solution from each well and apply it to the modified Frey solid medium. If the number of colonies is less than 5, it is the MBC value.

[0038] 3. Results

[0039] As shown in Table 1, when the concentration of magnolol is 15.625 μg / mL, it has an inhibitory effect on the growth of Mycoplasma gallisepticum and Mycoplasma synoviae. When the concentration of magnolol is 31.25 μg / mL, it has a bactericidal effect on Mycoplasma gallisepticum and Mycoplasma synoviae.

[0040] Table 1 Minimum inhibitory concentration and minimum bactericidal concentration of magnolol against Mycoplasma gallisepticum and Mycoplasma synoviae

[0041]

[0042] Embodiment 2:

[0043] The inhibitory effect of magnolol on the growth of Mycoplasma gallisepticum and Mycoplasma synoviae increased with the increase of concentration:

[0044] Referring to the minimum inhibitory concentration of magnolol determined in Example 1, magnolol solution was added to the mycoplasma suspension grown to the logarithmic phase to make the final concentrations 1 / 2MIC, 1MIC, 2MIC, and 4MIC, respectively. The mycoplasma suspension without magnolol was used as a positive control, and the modified Frey's medium alone was used as a negative control;

[0045] The cells were cultured in a 37°C 5% CO2 incubator, and the CCU of the mycoplasma suspension at each drug concentration was determined at 0, 12, 24, 36, and 48 hours, respectively, to obtain the growth curves of Mycoplasma gallisepticum and Mycoplasma synoviae at different magnolol concentrations.

[0046] Depend on Figure 1 , Figure 2It can be seen that when the final concentration of magnolia officinalis is 7.8125μg / mL and 15.625μg / mL (i.e. 1 / 2MIC and 1MIC), compared with the control group without magnolia officinalis, the growth of the two mycoplasmas was inhibited at each time point, and was dose-dependent with the concentration of magnolia officinalis solution. When the final concentration of magnolia officinalis is greater than or equal to 31.25μg / mL (i.e. 2MIC), both mycoplasmas are completely killed.

[0047] The above results show that magnolol can not only inhibit the growth of Mycoplasma gallisepticum and Mycoplasma synoviae, but also kill Mycoplasma gallisepticum and Mycoplasma synoviae.

[0048] Embodiment 3:

[0049] Determination of the minimum inhibitory concentration and minimum bactericidal concentration of EGCG against Mycoplasma gallisepticum and Mycoplasma synoviae:

[0050] 1. Materials

[0051] Modified Frey's medium is used for drug sensitivity experiments to detect the antibacterial efficacy of drugs.

[0052] 2. Test methods

[0053] The mycoplasma suspension cultured to the logarithmic growth phase was diluted to an appropriate concentration and added to sterile 96-well plates. 100 μL of the diluted mycoplasma suspension was added to wells 1 to 11 to make the final concentration of the mycoplasma suspension in each well 10 5 CCU / mL;

[0054] The EGCG solution was diluted in multiples with modified Frey's medium, and different concentrations of EGCG solutions were added to the above 96-well plate. The diluted EGCG solution was added to wells 1 to 10, 100 μL per well, and 100 μL of modified Frey's medium was added to well 11 to form a 200 μL mycoplasma suspension as a growth control. Only 200 μL of modified Frey's medium was added to well 12 as a negative control.

[0055] Place the 96-well plate in a 37°C 5% CO2 incubator for 48 hours, observe the color change of the culture medium in the 96-well plate, and determine the MIC value. Take the bacterial solution from each well and apply it to the modified Frey solid medium. If the number of colonies is less than 5, it is the MBC value.

[0056] 3. Results

[0057] As shown in Table 2, when the concentration of EGCG is 250 μg / mL, it has an inhibitory effect on the growth of Mycoplasma gallisepticum and Mycoplasma synoviae, and when the concentration of EGCG is 500 μg / mL, it has a bactericidal effect on Mycoplasma gallisepticum and Mycoplasma synoviae.

[0058] Table 2 Minimum inhibitory concentration and minimum bactericidal concentration of EGCG against Mycoplasma gallisepticum and Mycoplasma synoviae

[0059]

[0060] Embodiment 4:

[0061] The inhibitory effect of EGCG on the growth of Mycoplasma gallisepticum and Mycoplasma synoviae increased with the increase of concentration:

[0062] Referring to the minimum inhibitory concentration of EGCG determined in Example 3, EGCG solution was added to the mycoplasma suspension grown to the logarithmic phase to make the final concentrations 1 / 2MIC, 1MIC, 2MIC, 4MIC, and 8MIC, respectively. The mycoplasma suspension without EGCG was used as a positive control, and the modified Frey's medium alone was used as a negative control;

[0063] The cells were cultured in a 37°C 5% CO2 incubator, and the CCU of the mycoplasma suspension at each drug concentration was determined at 0, 12, 24, 36, and 48 hours, respectively, to obtain the growth curves of Mycoplasma gallisepticum and Mycoplasma synoviae at different EGCG concentrations.

[0064] Depend on Figure 3 , Figure 4 It can be seen that when the final concentration of EGCG was 125μg / mL and 250μg / mL (i.e., 1 / 2MIC and 1MIC), compared with the control group without EGCG, the growth of the two mycoplasmas was inhibited at each time point, and was dose-dependent with the concentration of EGCG solution. When the final concentration of EGCG was greater than or equal to 500μg / mL (i.e., 2MIC), both mycoplasmas were completely killed.

[0065] The above results show that EGCG can not only inhibit the growth of Mycoplasma gallisepticum and Mycoplasma synoviae, but also kill Mycoplasma gallisepticum and Mycoplasma synoviae.

[0066] Embodiment 5:

[0067] Checkerboard microdilution test was used to determine the synergistic antibacterial effect of magnolol and EGCG on Mycoplasma gallisepticum and Mycoplasma synoviae:

[0068] 1. Materials

[0069] Modified Frey's medium is used for drug sensitivity experiments to detect the antibacterial efficacy of drugs.

[0070] 2. Test methods

[0071] Dilute the mycoplasma suspension cultured to the logarithmic growth phase to an appropriate concentration, and add it to a sterile 96-well plate respectively. Add 100 μL of the diluted mycoplasma suspension to the 1st to 10th rows, so that the final concentration of mycoplasma suspension in each well is 10 5 CCU / mL. Add 200 μL of the mycoplasma suspension to the 11th row as a growth control, and add only 200 μL of the modified Frey's medium to the 12th row as a negative control.

[0072] Dilute the two compounds used in the experiment in a 96-well plate in a serial dilution manner. Add 50 μL of the diluted magnolol to the 96-well plate from left to right (1-10) in sequence, and add 50 μL of the diluted EGCG from top to bottom (A-H) in sequence, so that the final concentrations of magnolol are: 250 μg / mL, 125 μg / mL, 62.5 μg / mL, 31.25 μg / mL, 15.625 μg / mL, 7.813 μg / mL, 3.906 μg / mL, 1.953 μg / mL, 0.977 μg / mL, 0.488 μg / mL, and the final concentrations of EGCG are: 1000 μg / mL, 500 μg / mL, 250 μg / mL, 125 μg / mL, 62.5 μg / mL, 31.25 μg / mL, 15.626 μg / mL, 7.813 μg / mL.

[0073] Place the 96-well plate in an incubator at 37 °C with 5% CO2 for 48 h, observe the color change of the medium in the 96-well plate, and calculate the combined antibacterial index according to the minimum combined antibacterial concentration of the antibiotic and the compound.

[0074] The determination method is: synergistic antibacterial effect, FICI ≤ 0.5; additive effect, 0.5 < FICI ≤ 1; no effect, 1 < FICI ≤ 2; antagonistic effect, FICI > 2.

[0075] 3. Results

[0076] As can be seen from Table 3, when magnolol and EGCG are used in combination, the optimal concentrations of magnolol and EGCG are 1.953 μg / mL and 62.5 μg / mL respectively, and the fractional inhibitory concentration index against Mycoplasma gallisepticum is 0.375. When the concentration of magnolol is 1.953 - 3.906 μg / mL and the concentration of EGCG is 62.5 μg / mL, it has a synergistic antibacterial effect on the growth of Mycoplasma synoviae.

[0077] FICI calculation formula: FICI = MIC of drug A in combination / MIC of drug A alone + MIC of drug B in combination / MIC of drug B alone.

[0078] Table 3 Minimum inhibitory concentration and fractional inhibitory concentration index of magnolol and EGCG against Mycoplasma gallisepticum and Mycoplasma synoviae

[0079]

[0080] The above embodiments are preferred implementation modes of the present invention, but the implementation modes of the present invention are not limited to the above embodiments. Any other changes, modifications, substitutions, combinations, and simplifications that do not deviate from the spirit and principles of the present invention should be equivalent replacement methods and are included in the protection scope of the present invention.

Claims

1. Magnolia officinalis in the preparation of drugs for the treatment or prevention of Mycoplasma gallisepticum Mycoplasma Galliscepticum Mycoplasma synoviae Mycoplasma Synoviae Application in medicine.

2. Use of a magnolol composition in the preparation of a drug for treating or preventing Mycoplasma gallisepticum or Mycoplasma synoviae infection, wherein the only active ingredients of the magnolol composition are magnolol and EGCG.

3. The use according to claim 2, characterized in that: When used for preparing a drug for treating or preventing Mycoplasma gallisepticum infection, the mass ratio of magnolol to EGCG is 1:

32.

4. The use according to claim 2, characterized in that: When used for preparing a medicine for treating or preventing chicken synoviae Mycoplasma infection, the mass ratio of magnolol to EGCG is 1:16-32.